Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,138 public posts
Filter results
Staring at my unopened bottle of Orgovyx
That pursuit creates the risk of becoming
castration
-resistant, from what I've learned by reading case studies. The treatment therapies must get stronger and stronger after that. So I'm prepared to live with the tumors but slow their growth.
That pursuit creates the risk of becoming
castration
-resistant, from what I've learned by reading case studies. The treatment therapies must get stronger and stronger after that. So I'm prepared to live with the tumors but slow their growth.
mababa
in
Advanced Prostate Cancer
5 months ago
Phase III Study: Saruparib Combo with New Hormonal Agents in mCSPC +/- HRR Mutations: AUA 2024 EvoPAR-Prostate01 Trial
Neeraj Agarwal discussing EvoPAR-Prostate01, a phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic
castration
-sensitive prostate cancer (mCSPC) with and without homologous recombination repair
Neeraj Agarwal discussing EvoPAR-Prostate01, a phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic
castration
-sensitive prostate cancer (mCSPC) with and without homologous recombination repair
God_Loves_Me
in
Advanced Prostate Cancer
2 months ago
Four years of ADT, pros/cons
Four years of Lupron + abiraterone Pros: I'm still alive and
castration
sensitive, spine met not growing or painful Cons: Zero libido, muscle loss, fat gain, hot flashes, blueberry-size testicles, BP increase, body hair loss...
Four years of Lupron + abiraterone Pros: I'm still alive and
castration
sensitive, spine met not growing or painful Cons: Zero libido, muscle loss, fat gain, hot flashes, blueberry-size testicles, BP increase, body hair loss...
Gearhead
in
Advanced Prostate Cancer
2 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Is Xtandi necessary or even helping me?
Could it just be driving my cancer towards
castration
resistance and more aggressiveness quicker than necessary? Any thoughts are welcome.
Could it just be driving my cancer towards
castration
resistance and more aggressiveness quicker than necessary? Any thoughts are welcome.
Benkaymel
in
Advanced Prostate Cancer
1 year ago
Is Xtandi necessary or even helping me?
Could it just be driving my cancer towards
castration
resistance and more aggressiveness quicker than necessary? Any thoughts are welcome.
Could it just be driving my cancer towards
castration
resistance and more aggressiveness quicker than necessary? Any thoughts are welcome.
Benkaymel
in
Fight Prostate Cancer
1 year ago
Masofaniten +Enzalutamide This could be a game changer...Science is coming to our aid
Masofaniten is currently being studied in an open-label, randomized Phase 2 clinical trial (NCT05075577) in combination with enzalutamide in patients with metastatic
castration
-resistant prostate cancer (mCRPC) naïve to second-generation antiandrogens.
Masofaniten is currently being studied in an open-label, randomized Phase 2 clinical trial (NCT05075577) in combination with enzalutamide in patients with metastatic
castration
-resistant prostate cancer (mCRPC) naïve to second-generation antiandrogens.
Scout4answers
in
Advanced Prostate Cancer
9 months ago
FDA ODAC -Lynparza (olaparib), PARP inhibitor, is only for metastatic castration-resistant PC patients whose tumors have a BRCA mutation.
The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic
castration
-resistant prostate cancer patients whose tumors have a BRCA mutation.
The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic
castration
-resistant prostate cancer patients whose tumors have a BRCA mutation.
JRPnSD
in
Advanced Prostate Cancer
1 year ago
Further treatment - Update
It seems now the cancer is
castration
resistant. I had my last PET scan in May without any findings.
It seems now the cancer is
castration
resistant. I had my last PET scan in May without any findings.
Jansverr
in
Advanced Prostate Cancer
1 year ago
My battle with castration resistant metastatic prostate cancer that had spread to the bones since 2021
What do I need to do after biopsy, surgery, chemotherapy, Abiraterone treatment and ailment seems to progress as I am always in intense pain and sleepless nights? My PSA hovers above 100.
What do I need to do after biopsy, surgery, chemotherapy, Abiraterone treatment and ailment seems to progress as I am always in intense pain and sleepless nights? My PSA hovers above 100.
emmaokeke
in
Advanced Prostate Cancer
1 year ago
Need to restage cancer
Due to being
castration
resistant and PSA rising while on Xtandi/Lupron, his MO says she needs scan(s) to restage his cancer. The problem is that my husband can't tolerate lying on his back for the duration and/or keep his arms raised above his head.
Due to being
castration
resistant and PSA rising while on Xtandi/Lupron, his MO says she needs scan(s) to restage his cancer. The problem is that my husband can't tolerate lying on his back for the duration and/or keep his arms raised above his head.
Shamrock46
in
Advanced Prostate Cancer
2 years ago
Talzenna approved by FDA
Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic
castration
-resistant prostate cancer (mCRPC).
Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic
castration
-resistant prostate cancer (mCRPC).
Magnus1964
in
Prostate Cancer Network
1 year ago
Dual ARi in mCRPCa - Antonarakis = 'Combo of 2 AR-directed agents should not be utilized in clinical practice at this time', MedPage 7/20/23
[/i] A phase III trial found no survival benefit for the combination of enzalutamide and abiraterone in men with metastatic
castration
-resistant prostate cancer, but it did find something else noteworthy.
[/i] A phase III trial found no survival benefit for the combination of enzalutamide and abiraterone in men with metastatic
castration
-resistant prostate cancer, but it did find something else noteworthy.
cujoe
in
Fight Prostate Cancer
1 year ago
The term 'Castration' resistant/sensitive is offensive
The term '
Castration
' resistant or sensitive has bothered me since I was told I had stage 4 metastatic
castration
sensitive PCa. Why isn't it called 'ADT' resistant/sensitive?
The term '
Castration
' resistant or sensitive has bothered me since I was told I had stage 4 metastatic
castration
sensitive PCa. Why isn't it called 'ADT' resistant/sensitive?
austinsurvivor
in
Advanced Prostate Cancer
2 years ago
Neuroendocrine Prostate cancer (NEPC) questions.
Introduction Neuroendocrine prostate cancer (NEPC) is rare, accounting for only about 0.2–1% of whole prostate cancers.1 On the other hand, it has been reported that 17–40% of the
castration
-resistant prostatic cancers under anti-androgen therapies changed into NEPC.2 The longer anti-androgen therapy
Introduction Neuroendocrine prostate cancer (NEPC) is rare, accounting for only about 0.2–1% of whole prostate cancers.1 On the other hand, it has been reported that 17–40% of the
castration
-resistant prostatic cancers under anti-androgen therapies changed into NEPC.2 The longer anti-androgen therapy
GeorgeGlass
in
Advanced Prostate Cancer
2 months ago
Clinical Trial Considerations??
Niraparib (a PARP inhibitor) was recently FDA approved for prostate cancer treatment, primarily for men with
castration
-resistant cancer. It’s been used with cervical and ovarian cancer. This Phase I/II study is to establish the maximum tolerable dose of the drug.
Niraparib (a PARP inhibitor) was recently FDA approved for prostate cancer treatment, primarily for men with
castration
-resistant cancer. It’s been used with cervical and ovarian cancer. This Phase I/II study is to establish the maximum tolerable dose of the drug.
CubFan
in
Prostate Cancer Network
9 months ago
Does anyone have experience with Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer:
My oncologist told me today that this is the hottest trial going right now and he would consider this for me in the future. I’m curious if anyone has any experience with this treatment and is willing to share. https://pubmed.ncbi.nlm.nih.gov/33172323/
My oncologist told me today that this is the hottest trial going right now and he would consider this for me in the future. I’m curious if anyone has any experience with this treatment and is willing to share. https://pubmed.ncbi.nlm.nih.gov/33172323/
No_stone_unturned
in
Advanced Prostate Cancer
10 months ago
Study says orchiectomy has higher risks for fracture than chemical castration. I wonder why.
https://www.empr.com/home/news/prostate-cancer-adt-increases-bone-fracture-risk/?utm_medium=email&utm_source=rasa_io&utm_campaign=newsletter
https://www.empr.com/home/news/prostate-cancer-adt-increases-bone-fracture-risk/?utm_medium=email&utm_source=rasa_io&utm_campaign=newsletter
rsgdmd
in
Advanced Prostate Cancer
1 year ago
New results soon (hopefully): A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Not the latest, but some more insight, since results should be on their way https://clinicaltrials.ucsf.edu/trial/NCT03575819 but they are already working on another CD46-targeted alpha therapy based on YS5, a radioimmunoconjugate. https://jeccr.biomedcentral.com/articles/10.1186/s13046-023-02636
Not the latest, but some more insight, since results should be on their way https://clinicaltrials.ucsf.edu/trial/NCT03575819 but they are already working on another CD46-targeted alpha therapy based on YS5, a radioimmunoconjugate. https://jeccr.biomedcentral.com/articles/10.1186/s13046-023-02636
Maxone73
in
Advanced Prostate Cancer
8 months ago
Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC - MedPage Today, November 1, 2023
[/i] [i]A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic
castration
-resistant prostate cancer (mCRPC), according to results from the phase III randomized CABASTY trial.
[/i] [i]A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic
castration
-resistant prostate cancer (mCRPC), according to results from the phase III randomized CABASTY trial.
CaptnMojoe
in
Fight Prostate Cancer
9 months ago
ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC
ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC October 27, 2023 Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic
castration
-resistant prostate cancer in the phase 1/2 study ONCT-534-101.
ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC October 27, 2023 Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic
castration
-resistant prostate cancer in the phase 1/2 study ONCT-534-101.
Scout4answers
in
Advanced Prostate Cancer
9 months ago
1
...
8
9
10
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1015 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest